GlassScriptPhysician profile
David L Porter
NPI 1780627075
$139,588.14
in general payments reported to CMS, 2019-2025
19 companies · $25K in 2025
The $25K reported for 2025 was more than what 94% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56K · 2020: $6,125 · 2021: $19K · 2022: $15K · 2023: $12K · 2024: $5,485 · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $33K · Travel and Lodging: $5,151 · Food and Beverage: $3,198 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,000 · Gift: $55.00 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $32,616.83 |
| Travel and Lodging | $5,150.62 |
| Food and Beverage | $3,198.15 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,000.00 |
| Gift | $55.00 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $35,566.38 | 2019-2025 | Kymriah |
| Kite Pharma, INC. | $31,724.86 | 2019-2025 | Tecartus, Yescarta |
| Novartis Pharma Ag | $21,420.17 | 2019-2024 | Kymriah |
| Incyte Corporation | $15,459.66 | 2019-2025 | Niktimvo |
| Celgene Corporation | $10,218.67 | 2019-2025 | Abecma |
| National Marrow Donor Program | $7,916.43 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $5,896.00 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $2,700.00 | 2021 | |
| Sanofi-Aventis U.S. LLC | $2,187.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $2,160.26 | 2024 | |
| Jazz Pharmaceuticals INC. | $2,120.00 | 2021 | |
| Adc Therapeutics America, INC. | $700.00 | 2023 | |
| Genentech USA, INC. | $495.13 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $413.33 | 2024 | |
| Cardinal Health 110 LLC | $387.50 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $81.59 | 2024 | Epkinly |
| Mckesson Sourcing Services, INC. | $62.67 | 2024 | |
| Gilead Sciences, INC. | $62.50 | 2025 | |
| Janssen Pharmaceuticals, INC | $15.99 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Porter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.